ArticleKidney international reports2022

Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin.

Michelle A Hladunewich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.